An immunogenic personal neoantigen vaccine for patients with melanoma.

doi:10.1038/nature22991

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

An immunogenic personal neoantigen vaccine for patients with melanoma.

Nature - 13 Jul 2017

Ott Patrick A, Hu Zhuting, Keskin Derin B, Shukla Sachet A, Sun Jing, Bozym David J, Zhang Wandi, Luoma Adrienne, Giobbie-Hurder Anita, Peter Lauren, Chen Christina, Olive Oriol, Carter Todd A, Li Shuqiang, Lieb David J, Eisenhaure Thomas, Gjini Evisa, Stevens Jonathan, Lane William J, Javeri Indu, Nellaiappan Kaliappanadar, Salazar Andres M, Daley Heather, Seaman Michael, Buchbinder Elizabeth I, Yoon Charles H, Harden Maegan, Lennon Niall, Gabriel Stacey, Rodig Scott J, Barouch Dan H, Aster Jon C, Getz Gad, Wucherpfennig Kai, Neuberg Donna, Ritz Jerome, Lander Eric S, Fritsch Edward F, Hacohen Nir, Wu Catherine J

Abstract excerpt

Effective anti-tumour immunity in humans has been associated with the presence of T cells directed at cancer neoantigens, a class of HLA-bound peptides that arise from tumour-specific mutations. They are highly immunogenic because they are not present in normal tissues and hence bypass central thymic tolerance. Although neoantigens were long-envisioned as optimal targets for an anti-tumour immune response, their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigens, Neoplasm

Share to Cancer Vaccines

Share to CD4-Positive T-Lymphocytes

Share to CD8-Positive T-Lymphocytes

Share to Histocompatibility Antigens Class II

Share to Machine Learning

Share to Programmed Cell Death 1 Receptor

Source

Open in PubMed Open full text

Identifiers

PMID: 28678778
DOI: 10.1038/nature22991
PMCID: PMC5577644

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An immunogenic personal neoantigen vaccine for patients with melanoma.PMID 28678778Read ↗

New emerging targets in cancer immunotherapy: the role of neoantigensSemantic proximity Read ↗

Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy.Semantic proximity Read ↗

Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.Semantic proximity Read ↗

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.Semantic proximity Read ↗

Characterizing neoantigens for personalized cancer immunotherapy.Semantic proximity Read ↗

Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and ImmunotherapySemantic proximity Read ↗

Neoantigen-based cancer immunotherapySemantic proximity Read ↗

Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapySemantic proximity Read ↗

Progress in Neoantigen Targeted Cancer ImmunotherapiesSemantic proximity Read ↗

Advances in personalized neoantigen vaccines for cancer immunotherapy.Semantic proximity Read ↗

Identification and Targeting of Mutant Peptide Neoantigens in Cancer ImmunotherapySemantic proximity Read ↗

Synthetic multiepitope neoantigen DNA vaccine for personalized cancer immunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.